ERCC5/XPG, ERCC1, and BRCA1 gene status and clinical benefit of trabectedin in patients with soft tissue sarcoma

Cancer

Volumn 117, Issue 15, 2011, Pages 3445-3456

  Italiano, Antoine ^a,b   Laurand, Armelle ^b   Laroche, Audrey ^b   Casali, Paolo ^c   Sanfilippo, Roberta ^c   Le Cesne, Axel ^d   Judson, Ian ^e   Blay, Jean Yves ^f,g   Ray Coquard, Isabelle ^f   Bui, Binh ^a   Coindre, Jean Michel ^a,b   Nieto, Antonio ^h   Tercero, Juan Carlos ^h   Jimeno, Jose ⁱ   Robert, Jacques ^a,b   Pourquier, Philippe ^a,b  

^a INSTITUT BERGONIÉ   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d INSTITUT GUSTAVE ROUSSY   (France)

^e ROYAL MARSDEN HOSPITAL   (United Kingdom)

^f CENTRE LÉON BÉRARD   (France)

^g CENTRE DE RECHERCHE EN CANCÉROLOGIE DE LYON   (France)

^h PHARMAMAR S A   (Spain)

ⁱ USP Dexeus   (Spain)

Author keywords

BRCA1; DNA repair; ERCC1; ERCC5; Polymorphism; predictive markers; Sarcoma

Indexed keywords

ADENINE; ASPARTIC ACID; CYTOSINE; GUANINE; MESSENGER RNA; THYMINE; TRABECTEDIN;

ADOLESCENT; ADULT; ADVANCED CANCER; AGED; ALLELE; ARTICLE; CANCER SURVIVAL; CHEMOSENSITIVITY; CODON; CONTINUOUS INFUSION; CONTROLLED STUDY; ERCC1 GENE; ERCC5 GENE; EXCISION REPAIR; FEMALE; GENE; GENE EXPRESSION; HAPLOTYPE; HOMOLOGOUS RECOMBINATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; ONCOGENE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SINGLE NUCLEOTIDE POLYMORPHISM; SOFT TISSUE SARCOMA; SURVIVAL RATE; SURVIVAL TIME;

EID: 79960698325     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25925     Document Type: Article

References (32)

1. Blay J, Penel N, Italiano A, et al. Trabectedin for advanced sarcomas failing doxorubicin: analysis of 189 unreported patients in a compassionate use program [abstract]. J Clin Oncol. 2009; 27 (15S). Abstract 10574.
2. Demetri GD, Chawla SP, von Mehren M, et al. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of 2 different schedules. J Clin Oncol. 2009; 27: 4188-4196.
3. Garcia-Carbonero R, Supko JG, Manola J, et al. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol. 2004; 22: 1480-1490. (Pubitemid 41103631)
4. Le Cesne A, Blay JY, Judson I, et al. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group trial. J Clin Oncol. 2005; 23: 576-584. (Pubitemid 46224235)
5. Yovine A, Riofrio M, Blay JY, et al. Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J Clin Oncol. 2004; 22: 890-899. (Pubitemid 41103601)
6. Damia G, Silvestri S, Carrassa L, et al. Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways. Int J Cancer. 2001; 92: 583-588. (Pubitemid 32319434)
7. Erba E, Bergamaschi D, Bassano L, et al. Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action. Eur J Cancer. 2001; 37: 97-105. (Pubitemid 32119366)
8. Herrero AB, Martin-Castellanos C, Marco E, Gago F, Moreno S., Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin. Cancer Res. 2006; 66: 8155-8162. (Pubitemid 44299183)
9. Soares DG, Escargueil AE, Poindessous V, et al. Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743. Proc Natl Acad Sci U S A. 2007; 104: 13062-13067. (Pubitemid 351737593)
10. Takebayashi Y, Pourquier P, Zimonjic DB, et al. Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. Nat Med. 2001; 7: 961-966. (Pubitemid 32756435)
11. Hoeijmakers JH., DNA damage, aging, and cancer. N Engl J Med. 2009; 361: 1475-1485.
12. Moynahan ME, Jasin M., Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis. Nat Rev Mol Cell Biol. 2010; 11: 196-207.
13. D'Incalci M, Erba E, Damia G, et al. Unique features of the mode of action of ET-743. Oncologist. 2002; 7: 210-216. (Pubitemid 34651224)
14. Stevens EV, Nishizuka S, Antony S, et al. Predicting cisplatin and trabectedin drug sensitivity in ovarian and colon cancers. Mol Cancer Ther. 2008; 7: 10-18.
15. Huen MS, Sy SM, Chen J., BRCA1 and its toolbox for the maintenance of genome integrity. Nat Rev Mol Cell Biol. 2009; 11: 138-148.
16. Martinez N, Sanchez-Beato M, Carnero A, et al. Transcriptional signature of ecteinascidin 743 (Yondelis, trabectedin) in human sarcoma cells explanted from chemo-naive patients. Mol Cancer Ther. 2005; 4: 814-823. (Pubitemid 40767126)
17. Gossage L, Madhusudan S., Cancer pharmacogenomics: role of DNA repair genetic polymorphisms in individualizing cancer therapy. Mol Diagn Ther. 2007; 11: 361-380. (Pubitemid 350274404)
18. Robert J, Morvan VL, Smith D, Pourquier P, Bonnet J., Predicting drug response and toxicity based on gene polymorphisms. Crit Rev Oncol Hematol. 2005; 54: 171-196. (Pubitemid 40693684)
19. Hostein I, Menard A, Bui BN, et al. Molecular detection of the synovial sarcoma translocation t(X;18) by real-time polymerase chain reaction in paraffin-embedded material. Diagn Mol Pathol. 2002; 11: 16-21. (Pubitemid 34171207)
20. Nouspikel T, Lalle P, Leadon SA, Cooper PK, Clarkson SG., A common mutational pattern in Cockayne syndrome patients from xeroderma pigmentosum group G: implications for a second XPG function. Proc Natl Acad Sci U S A. 1997; 94: 3116-3121. (Pubitemid 27157273)
21. Kim HT, Lee JE, Shin ES, et al. Effect of BRCA1 haplotype on survival of non-small-cell lung cancer patients treated with platinum-based chemotherapy. J Clin Oncol. 2008; 26: 5972-5979.
22. Shim HJ, Yun JY, Hwang JE, et al. BRCA1 and XRCC1 polymorphisms associated with survival in advanced gastric cancer treated with taxane and cisplatin. Cancer Sci. 2010; 101: 1247-1254.
23. Vilmar A, Sorensen JB., Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature. Lung Cancer. 2009; 64: 131-139.
24. Viguier J, Boige V, Miquel C, et al. ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer. Clin Cancer Res. 2005; 11: 6212-6217. (Pubitemid 41262950)
25. Grosso F., Trabectedin in soft tissue sarcomas (STS) carrying a chromosomal translocation: an exploratory analysis. Abstract 900. Paper presented at: Connective Tissue Oncology Society (CTOS) 13th Annual Meeting; November 1-3, 2007; Seattle, Wash.
26. Grosso F, Sanfilippo R, Virdis E, et al. Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series. Ann Oncol. 2009; 20: 1439-1444.
27. Forni C, Minuzzo M, Virdis E, et al. Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors. Mol Cancer Ther. 2009; 8: 449-457.
28. Cass I, Baldwin RL, Varkey T, Moslehi R, Narod SA, Karlan BY., Improved survival in women with BRCA-associated ovarian carcinoma. Cancer. 2003; 97: 2187-2195. (Pubitemid 36444059)
29. Chappuis PO, Goffin J, Wong N, et al. A significant response to neoadjuvant chemotherapy in BRCA1/2 related breast cancer. J Med Genet. 2002; 39: 608-610. (Pubitemid 34864568)
30. Goffin JR, Chappuis PO, Begin LR, et al. Impact of germline BRCA1 mutations and overexpression of p53 on prognosis and response to treatment following breast carcinoma: 10-year follow-up data. Cancer. 2003; 97: 527-536. (Pubitemid 36125829)
31. Kirova YM, Stoppa-Lyonnet D, Savignoni A, Sigal-Zafrani B, Fabre N, Fourquet A., Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy. Eur J Cancer. 2005; 41: 2304-2311. (Pubitemid 41415607)
32. Chibon F, Lagarde P, Salas S, et al. Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to genome complexity. Nat Med. 2010; 16: 781-787.